AN UPDATED TWO-YEAR SURVIVAL ANALYSIS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (R/R-LBCL)

被引：1
|
作者：
Diakite, I [1 ]
Lin, V. W. [2 ]
Klijn, S. [3 ]
Navale, L. [2 ]
Purdum, A. G. [2 ]
Fenwick, E. [4 ]
Botteman, M. [1 ]
van Hout, B. [5 ]
机构：
[1] Pharmerit Int, Bethesda, MD USA
[2] Kite, Santa Monica, CA USA
[3] Pharmerit Int, Rotterdam, Netherlands
[4] Pharmerit Int, Oxford, England
[5] Univ Sheffield, Sheffield, S Yorkshire, England
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.050
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
MS2
引用
收藏
页码：S41 / S41
页数：1
相关论文
共 50 条
  • [31] Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Chaganti, Sridhar
    Cwynarski, Kate
    Cunningham, David
    Locke, Frederick L.
    Miklos, David B.
    Jacobson, Caron A.
    Perales, Miguel-Angel
    Kersten, Marie Jose
    Oluwole, Olalekan O.
    Ghobadi, Armin
    Rapoport, Aaron P.
    McGuirk, Joseph P.
    Pagel, John M.
    Munoz, Javier
    Farooq, Umar
    van Meerten, Tom
    Reagan, Patrick M.
    Sureda, Anna
    Flinn, Ian W.
    Vandenberghe, Peter
    Song, Kevin W.
    Dickinson, Michael
    Minnema, Monique C.
    Riedell, Peter A.
    Leslie, Lori A.
    Yang, Yin
    Filosto, Simone
    Schupp, Marco
    To, Christina
    Cheng, Paul
    Gordon, Leo I.
    Radford, John
    Westin, Jason R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 20 - 22
  • [32] Retreatment (ReTx) of patients (Pts) with refractory large B cell lymphoma (LBCL) sith Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
    Locke, F. L.
    Bartlett, N. L.
    Jacobson, C. A.
    Oluwole, O. O.
    Munoz, J.
    Lekakis, L. J.
    Topp, M. S.
    Avivi, I
    Kim, J. J.
    Chu, R.
    Zheng, L.
    Rossi, J. M.
    Bot, A.
    Neelapu, S. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 57 - 57
  • [33] Retreatment of Patients With Refractory Large B Cell Lymphoma With Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
    Locke, Frederick
    Bartlett, Nancy
    Jacobson, Caron
    Oluwole, Olalekan
    Munoz, Javier
    Lekakis, Lazaros
    Topp, Max
    Avivi, Irit
    Kim, Jenny
    Chu, Rong
    Zheng, Lianqing
    Rossi, John
    Bot, Adrian
    Neelapu, Sattva
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S21 - S22
  • [34] Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
    Locke, Frederick Lundry
    Bartlett, Nancy L.
    Jacobson, Caron A.
    Oluwole, Olalekan O.
    Munoz, Javier
    Lekakis, Lazaros J.
    Topp, Max S.
    Avivi, Irit
    Kim, Jenny J.
    Chu, Rong
    Zheng, Lianqing
    Rossi, John M.
    Bot, Adrian
    Neelapu, Sattva Swarup
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] Circulating tumor DNA (ctDNA) by clonoSEQ to monitor residual disease after axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL)
    Miles, Brodie
    Mao, Daqin
    Vardhanabhuti, Saran
    To, Christina Ann
    Schupp, Marco Andreas
    Shahani, Shilpa
    Xu, Hairong
    Munoz, Javier
    Westin, Jason
    Shen, Rhine
    Filosto, Simone
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)
    Oluwole, Olalekan O.
    Forcade, Edouard
    Muñoz, Javier
    de Guibert, Sophie
    Vose, Julie M.
    Bartlett, Nancy L.
    Lin, Yi
    Deol, Abhinav
    McSweeney, Peter A.
    Goy, Andre H.
    Kersten, Marie Jose
    Jacobson, Caron
    Farooq, Umar
    Minnema, Monique C.
    Thieblemont, Catherine
    Timmerman, John M.
    Stiff, Patrick
    Avivi, Irit
    Tzachanis, Dimitrios
    Kim, Jenny J.
    Zheng, Yan
    Shen, Rhine R.
    Vardhanabhuti, Saran
    Van Meerten, Tom
    BLOOD, 2021, 138
  • [37] Matching- adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
    Oluwole, O. O.
    Ray, M. D.
    Chen, J. M.
    Chan, K.
    Zhang, I.
    Keeping, S.
    Smith, H.
    Spooner, C. L. Bellasis
    Patel, A. R.
    Locke, F. L.
    ANNALS OF ONCOLOGY, 2023, 34 : S548 - S548
  • [38] Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and glofitamab (glofit) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
    Locke, F. L.
    Chen, J. M.
    Chan, K.
    Ray, M. D.
    Zhang, I.
    Keeping, S.
    Fu, C.
    Patel, A. R.
    Oluwole, O. O.
    ANNALS OF ONCOLOGY, 2023, 34 : S549 - S549
  • [39] Retreatment (reTx) of Patients with Refractory Large B Cell Lymphoma with Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
    Locke, Frederick L.
    Bartlett, Nancy L.
    Jacobson, Caron A.
    Oluwole, Olalekan O.
    Munoz, Javier
    Lekakis, Lazaros J.
    Topp, Max S.
    Avivi, Irit
    Kim, Jenny J.
    Chu, Rong
    Zheng, Lianqing
    Rossi, John M.
    Bot, Adrian
    Neelapu, Sattva S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S265 - S265
  • [40] Clinical Outcomes with Prophylactic Corticosteroid Use for Axicabtagene Ciloleucel (axicel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/ R LBCL): A Multicenter Analysis
    Vuyyala, Sowjanya
    Corraes, Andre De Menezes Silva
    Bailey, Megumi
    Iqbal, Madiha
    Munoz, Javier L.
    Hunter, Bradley
    Bansal, Radhika
    Patel, Krish
    Kharfan-Dabaja, Mohamed A.
    Rosenthal, Allison C.
    Wang, Yucai
    Paludo, Jonas
    Johnston, Patrick B.
    Bennani, N. Nora
    Villasboas, J. C. C.
    Durani, Urshila
    Ansell, Stephen M.
    Lin, Yi
    Khurana, Arushi
    BLOOD, 2023, 142
12345